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Abstract 
BACKGROUND: Neonatal encephalopathy is a heterogeneous syndrome characterised by signs of central 
nervous system dysfunction in the newborn. Matrix metalloproteinase-9(MMP-9) increases the blood-brain barrier 
permeability, and their inhibitors can reduce its damage. MMP-9 has been implicated specifically in cerebral 
ischemia. 
AIM: To measure serum MMP-9 in neonatal hypoxic-ischemic encephalopathy and evaluate its correlation to the 
severity of early prediction and treatment. 
METHODS: its case-control study. The serum concentration of MMP-9 was determined by ELISA in 100 hypoxic 
neonates and 50 healthy neonates of matched age and sex who served as controls. 
RESULTS: In our present study the serum MMP-9 level was significantly higher at p = 0.0001 in hypoxic-ischemic 
full-term newborns (176.7 ± 68.7 ng/ml)as compared to control newborn (69.4 ± 34.85 ng/ml)and it was 
significantly higher at p = 0.0075 in hypoxic-ischemic preterm newborn (171.2 ± 132.9 ng/ml) when compared to 
control newborn (72.54 ± 36.74 ng/ml),also MMP-9 was significantly higher at Sarnat stage III at p = 0.0001. 
CONCLUSION: Serum MMP-9 level was significantly higher in hypoxic-ischemic newborns, and significantly 
increased with severity, so we suggest that serum MMP-9 level is important for predicting neurological sequel and 
severity in neonatal encephalopathy. 
 
 
 
 
 
Introduction 
 
Neonatal encephalopathy is a syndrome that 
has signs of central nervous system dysfunction in 
newborns and infants. Clinical suspicion of neonatal 
encephalopathy should be considered in any infant 
showing convulsions, an abnormal level of 
consciousness, feeding problems, apnea, aspiration, 
tone and reflex abnormalities, and hearing 
abnormalities [1], [2]. 
Perinatal asphyxia happens in 2 to 10 per 
1000 newborn that are born at term, and neurological 
dysfunctions are present in 25% to 28% of the 
affected infants. Asphyxia is inversely related to 
gestational age and birth weight. It occurs in 9% of 
infants below thirty-six weeks of gestation and 0.5% of 
infants more than 36 weeks of gestation [3]. 
The incidence of hypoxic-ischemic 
encephalopathy in developed countries is 1.5 per 
1000 live births, while it varies between 2.3-26.5 per 
1000 live births in developing countries [4]. However, 
in most developing countries, including Egypt, the 
incidence and outcomes of hypoxic-ischemic 
encephalopathy are not well documented. One of the 
studies estimated the rate of neonatal mortality in 
Egypt as 25 per 1000 live births, almost all of the 
mortality occurring in the first week of life. Prematurity 
and its complications were responsible for the largest 
percentages of deaths (39%), followed by birth 
asphyxia and birth trauma as major causes [5]. 
Neonatal encephalopathy was once 
automatically referred to hypoxia-ischemia, but now it 
is well known that hypoxia-ischemia is one of many 
other possible mechanisms of neonatal 
encephalopathy. Whether a particular newborn's 
encephalopathy can be attributed to hypoxic-ischemic 
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brain injury is often not clear [6]. 
Stringent criteria were needed by some 
investigator for using the term neonatal 
encephalopathy, as ≥ 2 symptoms of encephalopathy 
lasing over twenty-four hours [7]. However, others 
need only a low 5-minute Apgar score [8]. Using of 
Apgar scores alone is problematic, as it may be low 
due to analgesia used by the mothers or premature 
labour or falsely normal in some cases of acute 
hypoxia-ischemic insult, or can be inflated in actual 
clinical practice [9]. 
Neonatal encephalopathy is mostly because 
of dysfunction of the central nervous system in full and 
preterm infants when neonatal encephalopathy is due 
to hypoxic-ischemic brain injury (anoxic brain insult) it 
is preferred to use the term hypoxic-ischemic 
encephalopathy (HIE) [10].  
Early Estimation of the severity degree of HIE 
is important for tailoring the medical intervention to 
decide whether or not to perform potentially 
neuroprotective therapies [11]. 
Matrix metalloproteinases are a group of 
proteases that physiologically adjust the extracellular 
matrix and basement membrane reconstruction [12]. 
Matrix metalloproteinase-9 increases the 
permeability of the blood-brain barrier. Matrix 
Metalloproteinases inhibitors can reduce blood-brain 
barrier damage [13]. 
Matrix metalloproteinase-9 has been included 
specifically in cerebral ischemia [14]. 
Neuroprotection following of MMP-9 inhibitors 
activation has been demonstrated previously in the 
brain of an adult after cerebral ischemia by using 
MMP-9 inhibitors [15]. To our knowledge, there are no 
studies evaluating the level or role of MMP-9 in 
neonatal hypoxic-ischemic encephalopathy. 
Our study aimed to measure the serum level 
of Matrix metalloproteinases-9 in neonatal hypoxic-
ischemic encephalopathy and evaluate its correlation 
to the severity for early prediction and treatment, 
which in turn will reduce the financial burden of the 
country. 
 
Subjects and Methods 
 
Subjects 
The present study was conducted 150 
newborns admitted to neonatal intensive care units in 
Nasser general hospital.  
They were divided into 2 groups 
Group I:  
Included 100 hypoxic neonates 70 of them 
are full-term, and 30 are preterm with a mean 
gestational age of ± 38 wks for full-term and ± 34 wks 
for preterm, 54 are males, and 46 are females, 
regarding the mode of delivery 37 were delivered with 
caesarean section and 63 by spontaneous vaginal 
delivery. They were diagnosed as having HIE as 
evidenced by the presence of at least 2 of the 
following criteria: 
- Evidence of fetal distress (abnormal fetal 
heart patterns and meconium-stained amniotic fluid). 
- Apgar score < 3 at one minute or < 6 at 5 
minutes. 
- Evidence of neonatal respiratory distress. 
- Umbilical cord arterial pH < 7.2 with base 
deficit > 10 mmol/l. 
- Abnormal neurological signs on examination 
are denoting HIE according to Sarnat staging [16]. 
Exclusion criteria 
- Neonatal sepsis. 
- Blood group incompatibility. 
- Babies born to preeclamptic mother. 
- Infant of diabetic mothers (IDM). 
 
Group II 
 Included 50 healthy neonates 35 of them 
were full-term and 15 were preterm, 20 of them were 
males, and 30 were females with a mean age of ± 39 
wks for full-term and 35 wks for preterm. Regarding 
mode of delivery, 28 were delivered with cesarean 
section and 22 by normal vaginal delivery, without 
signs of perinatal asphyxia. 
 
 Methods 
All newborns included were subjected to the 
following: 
- Full maternal history taking  
- Detailed antenatal and perinatal history.  
- Clinical examination including 1. Gestational 
age assessment: modified Ballard scoring system 
[17]; 2. Apgar scores estimation at 1 & 5 minutes to 
assess the presence of perinatal asphyxia [18]; 3. 
Vital signs: Blood pressure; 4. Head circumference; 5. 
Anthropometric measures; 6. Full cardiac, chest, 
abdominal and neurological examination and 7. 
Detailed neurological examination including A) Level 
of consciousness; B) Activity; C) Neuromuscular 
examination: Tone, power, position and stretch reflex; 
D) Primitive reflexes (suckling, Moro, grasp, rooting, 
glabellar and neck rigidity reflexes); E) Irritability; F) 
Seizures (type, responses to anticonvulsant drugs) 
and G) Sarnat and Sarnat staging according to [16]. 
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Laboratory investigations 
Venous or capillary blood samples were 
withdrawn on heparinised tubes for blood gas 
assessment. Moreover, peripheral blood samples 
were collected three ml venous blood sample was 
collected from each patient into a plain tube. After 
clotting for 30 minutes, serum was separated by 
centrifugation for 15 minutes at approximately 1000 x 
g, and samples were stored at -20°C till the assay. 
 
Methods of assay 
Blood gases were analysed by the 
GEMpremier3000 system analyser. 
 
Determination of serum MMP-9 
The quantitative determination of serum 
MMP-9 was done using the commercially available 
ELISA kit supplied by R&D Systems. 
 
Statistical analysis 
Standard computer program SPSS for 
Windows, release 23 (SPSS Inc, USA) was used for 
data entry and analysis. All numeric variables were 
expressed as mean ± standard deviation (SD). 
Comparison of different variables in various groups 
was made using student t-test followed by Duncan's 
multiple range tests with P < 0.05 selected as the level 
of the statistical significance. Comparisons of multiple 
subgroups were made, and Data are presented as M 
± SEM and analysed by one-way ANOVA followed by 
Tuckey Kramer post-test using Graph Pad Prism 
software. For all tests, a probability (p) less than 0.05 
was considered significant. 
 
 
Results 
 
As mentioned before this study included 100 
neonates with HIE and 50 healthy neonates of 
matched age and sex who served as controls.  
Table 1: Descriptive Data of group I (HIE) (N = 100) 
P Value Preterm N = 30 Full Term N = 70  
0.078 ±0.852 33.9 ± 1.436 38.8 Mean age (weeks) 
0.254 ±279.3 2205 ± 142 3220 Mean weight (gram) 
0.0987 ±0.8333 2.8 ± 0.9679 2.9 Mean apgar 1 min 
0.254 ±0.8751 5.65 ± 0.894 5.8 Mean apgar 5 min 
0.667 ±0.067 7 ± 0.0233 7.173 Mean PH 
0.98 ±132.9 171.2 ± 168.7 176.7 Mean MMP-9 (ng/ml) 
P < 0.05 was significant. Data are presented as mean ± SD; MMP-9: Matrix 
metalloproteinases-9; HIE: hypoxic-ischemic encephalopathy. 
 
 Descriptive, demographic and laboratory data 
of HIE patients and controls were shown in (Table 1, 2 
and 3). 
Table 2: Deceptive data of group II (control) (N = 50) 
Pvalue Preterm N = 15 Full Term N = 35  
0.45 35.25 ± 9.541 39.93±11.335 Mean age (weeks) 
0.142 2002 ± 258 3981 ± 311 Mean weight (gram) 
0.871 6.65 ± 0.299 7.133 ± 0.3519 Mean apgar 1 min 
0.5412 8.787 ± 0.398 9.267 ± 0.4577 Mean apgar 5 min 
0.0854 7.11 ± 0.0023 7.373 ± 0.0045 Mean PH 
0.145 72.54 ± 36.74 69.41 ± 34.85 Mean MMP- 9 (ng/ml) 
P < 0.05 was significant. -Data are presented as mean ±SD ;MMP-9: Matrix 
metalloproteinases-9. 
 
Table 4 showed that serum MMP-9 was 
significantly higher in full-term cases than in controls. 
Table 3: Descriptive data of both group regarding gender and 
mode of delivery  
Control 
N (%) = 50 
HIE 
N (%) = 100 
 
P 
Value 
Preterm 
N (%) = 15 
Full Term 
N (%) = 35 
P 
Value 
Preterm 
N (%) = 30 
Full Term 
N (%) = 70 
0.214 9(60)/6(40) 11(31.4)/24(68.5) 0.95 
 
16(53.3)/14(46.6) 38(54.2)/32(45.7) Gender 
(Male/Female 
0.121 8(53.3)/7(46.6) 14(40)/21(60) 
 
 
0.458 7(23.3)/23(76.6) 56(80)/14(20) Mode of delivery 
(Normal/C-section) 
P < 0.05 was significant. -Data are presented frequency (percentage); HIE: hypoxic-
ischemic encephalopathy. 
 
Also, there was a significant difference in 
mean PH and Apgar scores at 1 and 5 minutes 
between full-term cases and controls as PH was 
significantly lower in cases than controls, while there 
was an increase in Apgar score at 1 and 5 minutes in 
controls. 
Table 4: Comparison between Full Term cases and control 
P value Control (Full Term) N = 35 Cases (Full Term) N = 70  
0.087 39.93 ± 19.335 38.8 ± 18.436 Mean age (weeks) 
0.74 3981 ± 311 3220 ± 142 Mean weight (gram) 
0.0001 7.133 ± 0.3519 2.9 ± 0.9679 Mean apgar 1 min 
0.0001 9.267 ± 0.4577 5.8 ± 0.894 Mean apgar 5 min 
0.0001 7.373 ± 0.0045 7.173 ± 0.0233 Mean PH 
0.0001 69.41 ± 34.85 176.7 ± 68.7 Mean MMP-9 (ng/ml) 
P < 0.05 was significant; Data are presented as mean ±SD; MMP-9: Matrix 
metalloproteineases-9. 
  
Table 5 showed that serum MMP-9 was 
significantly higher in preterm cases than in controls. 
Also, there was a significant difference regarding 
mean PH and Apgar scores as PH was significantly 
lower in cases than controls while there was an 
increase in Apgar score at 1 and 5 minutes in 
controls. 
Table 5: Comparison between Preterm cases and control 
P value Control Preterm N = 15 Cases Preterm N = 30  
0.98 35.25 ± 9.541 33.9 ± 0.852 Mean age (weeks) 
0.254 2002 ± 258 2205 ± 279.3 Mean weight (gram) 
 0.0001 6.65 ± 0.299 2.8 ± 0.8333 Mean apgar 1 min 
0.0001  8.787 ± 0.398 5.65 ± 0.8751 Mean apgar 5 min 
0.0001  7.11 ± 0.0023 7 ± 0.067 Mean PH 
0.0075  72.54 ± 36.74 171.2 ± 132.9 Mean MMP-9 (ng/ml) 
P < 0.05 was significant; Data are presented as mean ± SD.; MMP-9: Matrix 
metalloproteinases-9. 
 
According to Sarnat stages of HIE, There was 
a significant difference in mean MMP-9 in different 
stages as it was significantly higher in stage 3 when 
compared with stage 2 and 1 (Table 6). 
Table 6: Comparison between MMP-9 levels in HIE group 
regarding Sarnat stages 
P-value Stage 3 Stage 2 Stage 1  
0.0001 189.2 ± 139.8 134.2 ± 89.39 123.5 ± 74.54 Mean MMP-9 
(ng/ml) 
P < 0.05 was significant; Data are presented as mean ± SD; MMP-9: Matrix 
metalloproteinases-9; HIE: hypoxic-ischemic encephalopathy. 
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Discussion  
 
Neonatal encephalopathy is a syndrome that 
has signs of central nervous system dysfunction in 
newborns and infants. Clinical suspicion of neonatal 
encephalopathy should be considered in any infant 
showing convulsions, an abnormal level of 
consciousness, feeding problems, apnea, aspiration, 
tone and reflex abnormalities, and hearing 
abnormalities [1], [2]. 
Prematurity and its complications were 
responsible for the largest percentages of deaths 
(39%), followed by birth asphyxia and birth trauma as 
major causes [5]. 
Early Estimation of the severity degree of HIE 
is important for tailoring the medical intervention to 
decide whether or not to perform potentially 
neuroprotective therapies [11]. 
Matrix metalloproteinases are a group of 
proteases that physiologically adjust the extracellular 
matrix and basement membrane reconstruction [12]. 
Matrix metalloproteinase-9 increases the 
permeability of the blood-brain barrier. Inhibitors of 
matrix Metalloproteinases can reduce the damage to 
the blood-brain barrier [13]. 
Matrix metalloproteinase-9 has been 
implicated specifically in cerebral ischemia [14]. 
Neuroprotection following inhibition of MMP-9 
activation has previously been demonstrated in the 
adult brain after cerebral ischemia by using MMP-9 
inhibitors [15]. 
The present study was conducted 150 
newborns admitted to neonatal intensive care units in 
Nasser general hospital.  
Included 100 hypoxic neonates 70 of them 
are full-term, and 30 are preterm with a mean 
gestational age of ± 38 wks for full-term and ± 34 wks 
for preterm, 54 are males, and 46 are females, 
regarding the mode of delivery 37 were delivered with 
cesarean section and 63 by spontaneous vaginal 
delivery.  
Fifty healthy neonates 35 of them were full-
term, and 15 were preterm, 20 of them were males, 
and 30 were females with a mean age of ± 39 wks for 
full-term and 35 wks for preterm. Regarding mode of 
delivery, 28 were delivered with cesarean section and 
22 by normal vaginal delivery, without signs of 
perinatal asphyxia. 
 Apgar score is one of the essential criteria for 
the diagnosis of perinatal asphyxia. Moreover, Apgar 
scores at 1 and 5 minutes were not significantly 
different between the cases and control in group l and 
group 2 newborns (Table 1 and 2). Table 4 & 5 
showed that Apgar score at 1 minute (2.9 ± 0.9679) in 
full-term HIE newborn which was significantly lower at 
p = 0.0001 compared to control newborn (7.1 ± 0.351) 
,and (2.8 ± 0.83) in preterm HIE newborn which was 
significantly lower compared to control newborn (6.6 ± 
0.29), also at 5 minutes, it was (5.8 ± 0.89) in full-term 
HIE newborn which was significantly lower at p 
=0.0001 compared to control full-term newborn (9.26 
± 0.45) and it was (5.65 ± 0.87) in preterm HIE 
newborn who was significantly lower compared to 
control preterm newborn (8.78 ± 0.39). These results 
are in agreement with Mostert al., [19] who reported 
that Apgar score could differentiate between the 
control groups and hypoxic groups. 
In our study pH was significantly different in 
preterm HIE newborns (7.0 ± 0.06) compared to 
control newborns (7.1 ± 0.0023) at p = 0.0001, also 
there was significant difference in HIE full-term 
newborns PH (7.1 ± 0.02) compared to control 
newborns (7.3 ± 0.0045) at p = 0.0001.These results 
are in a disagreement with khan et al., [20] who 
reported the insignificant difference in pH level in 
hypoxic and control groups. On the other hand this 
agrees with Johnston et al., [21],Ferriero, [22] and 
Fahey and King, [23] as they reported that low arterial 
umbilical cord pH had a strong, consistent, and 
temporal association with neonatal mortality and 
morbidity composite of hypoxic-ischaemic 
encephalopathy, seizures, and intraventricular 
haemorrhage or periventricular leucomalacia and long 
term outcome in the form of cerebral palsy. 
In our present study the mean serum MMP-9 
level was significantly higher at p = 0.0001 in HIE full-
term newborns (176.7 ± 68.7 ng/ml)as compared to 
control newborn (69.4 ± 34.85 ng/ml)and level of 
serum MMP-9 was significantly higher at p = 0.0075 in 
HIE preterm newborn (171.2 ± 132.9 ng/ml) when 
compared to control newborn (72.54 ± 36.74 ng/ml). 
These results are in agreement with Ashai et al., [15] 
who reported that on studying animal models of 
cerebral ischemia MMP-9 is regulated up early in 
injured tissue suggesting its involvement in neuronal 
death and brain damage. Moreover, MMP-9 inhibition 
through knockout models or drug treatments reduces 
infarction volume. On the other hand, this disagrees 
with Sunagawa et al., [24] who studied serum levels of 
MMP-9/TIMP on the day of birth in asphyxiated 
newborns and they demonstrated no statistically 
significant difference in MMP-9 levels between 
asphyxiated newborns and controls.  
According to Sarnat staging of HIE serum 
level of MMP-9 was 123.5 ± 74.54 ng/ml, 134.2 ± 
89.39 ng/ml and 189.2 ± 139.8 ng/ml in stages I, II 
and III respectively, which was significantly higher at p 
= 0.0001 with worsening of symptoms and signs in 
hypoxic newborns. These results are in agreement 
with Sunagawa et al., [24] who reported that MMP-9 
levels in asphyxiated newborns with neurological 
insult on birthday were significantly higher than those 
in asphyxiated newborn without sequelae also he 
suggested that high concentrations of MMP-9 on day 
of birth could injure the blood-brain barrier and causes 
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irreversible brain damage. Also, Tsuji et al., [25] who 
tested MMP-9 upregulation after focal cerebral 
ischemia, found that patients with high plasma levels 
of MMP-9 experience more brain injury with poor 
outcomes after cerebral ischemia. 
In conclusion, serum MMP-9 level is 
significantly higher in hypoxic-ischemic newborns, and 
significantly increased with severity, so we suggest 
that serum MMP-9 level is important for predicting 
neurological sequel and severity in neonatal 
encephalopathy.  
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